Although this may not happen today, it should not take long for the market to realise that Group Revenue so far this year is running at 8.0% compared with 7.5% for FY18. So, after stabilising the performance of standalone vets, performance has improved compared with the last update. The market should eventually like the already proven uptick in sales and the stabilisation of costs (with more cost savings predicted), because that should improve EBITDA substantially.
- Forums
- ASX - By Stock
- Ann: FY18 Full Year Results - Investor Presentation
Although this may not happen today, it should not take long for...
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GXL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online